Microread Genetics (stock code: 873723.NQ) is mainly engaged in the R&D, production and sales of multi-gene joint detection products, and provides technical services and innovative solutions for downstream customers based on the medium-throughput genetic detection technology platform, with a wide range of products and services Applied in forensic science, clinical medicine, industry and agriculture and other fields.

Guided by market demand, Microread Genetics fully utilizes its technical accumulation in the field of genetic testing, takes the medium-throughput fluorescent PCR-capillary electrophoresis platform as the core technology platform, and forms key capabilities such as testing equipment, testing reagents, and software system development and services. Committed to the technological progress and product development in the field of clinical medicine of major disease spectrum and the field of forensic science genetic testing, it has gradually become an innovative enterprise with the advantages of equipment, reagents and software integration in the domestic genetic testing field. A series of one-stop overall solutions have been launched, covering forensic DNA identification, DNA database construction, tumor drug use, reproductive genetics, drug guidance for cardiovascular and mental diseases, biopharmaceuticals, farming, animal husbandry and breeding, and general health.